T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease

NeuroImage: Clinical

Volumn 7, Issue , 2015, Pages 598-604

  Haris, Mohammad ^a,b   Yadav, Santosh K ^a   Rizwan, Arshi ^c   Singh, Anup ^b,d   Cai, Kejia ^b,e   Kaura, Deepak ^a   Wang, Ena ^a   Davatzikos, Christos ^f   Trojanowski, John Q ^f   Melhem, Elias R ^f   Marincola, Francesco M ^a   Borthakur, Arijitt ^b  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; CSF biomarkers; Medial temporal lobe; Mild cognitive impairment; T1rho

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; GRAY MATTER; HUMAN; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; TEMPORAL LOBE; WHITE MATTER; AREA UNDER THE CURVE; CEREBROSPINAL FLUID; COGNITIVE DYSFUNCTION; COMPUTER ASSISTED DIAGNOSIS; FEMALE; MALE; NEUROPSYCHOLOGICAL TEST; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; BIOMARKERS; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84924184565     PISSN: None     EISSN: 22131582     Source Type: Journal    
DOI: 10.1016/j.nicl.2015.02.016     Document Type: Article

References (52)

1. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., and Vanderstichele H. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch. Neurol. 58 3 2001 373 379 10.1001/archneur.58.3.373 11255440
2. Andreasen N., Sjögren M., and Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42 World J. Biol. Psychiatry 4 4 2003 147 155 10.1080/15622970310029912 14608585
3. Arai H., Morikawa Y., Higuchi M., Matsui T., and Clark C.M. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology Biochem. Biophys. Res. Commun. 236 2 1997 262 264 10.1006/bbrc.1997.6908 9240421
4. Aronen H.J., Ramadan U.A., Peltonen T.K., Markkola A.T., and Tanttu J.I. 3D spin-lock imaging of human gliomas Magn. Reson. Imaging 17 7 1999 1001 1010 10.1016/S0730-725X(99)00041-7 10463651
5. Barber R., Gholkar A., Scheltens P., Ballard C., and McKeith I.G. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies Neurology 52 6 1999 1153 1158 10.1212/WNL.52.6.1153 10214736
6. Blennow K. CSF biomarkers for mild cognitive impairment J. Intern. Med. 256 3 2004 224 234 10.1111/j.1365-2796.2004.01368.x 15324365
7. Borthakur A., Gur T., Wheaton A.J., Corbo M., and Trojanowski J.Q. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease J. Magn. Reson. Imaging 24 5 2006 1011 1017 10.1002/jmri.20751 17036339
8. Borthakur A., Mellon E., Niyogi S., Witschey W., and Kneeland J.B. Sodium and T1rho MRI for molecular and diagnostic imaging of articular cartilage N.M.R. Biomed. 19 7 2006 781 821 10.1002/nbm.1102 17075961
9. Borthakur A., Sochor M., Davatzikos C., Trojanowski J.Q., and Clark C.M. T1rho MRI of Alzheimer's disease Neuroimage 41 4 2008 1199 1205 10.1016/j.neuroimage.2008.03.030 18479942
10. Borthakur A., Wheaton A.J., Gougoutas A.J., Akella S.V., and Regatte R.R. In vivo measurement of T1rho dispersion in the human brain at 1.5 Tesla J. Magn. Reson. Imaging 19 4 2004 403 409 10.1002/jmri.20016 15065163
11. Chin J. Selecting a mouse model of Alzheimer's disease Methods Mol. Biol. 670 2011 169 189 10.1007/978-1-60761-744-0-13 20967591
12. Chincarini A., Bosco P., Calvini P., Gemme G., and Esposito M. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease Neuroimage 58 2 2011 469 480 10.1016/j.neuroimage.2011.05.083 21718788
13. Clerx L., van Rossum I.A., Burns L., Knol D.L., and Scheltens P. Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment Neurobiol. Aging 34 8 2013 2003 2013 10.1016/j.neurobiolaging.2013.02.002 23540941
14. Cummings J.L. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis Neurobiol. Aging 21 6 2000 845 861 10.1016/S0197-4580(00)00183-4 11124429
15. Davatzikos C., Fan Y., Wu X., Shen D., and Resnick S.M. Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging Neurobiol. Aging 29 4 2008 514 523 10.1016/j.neurobiolaging.2006.11.010 17174012
16. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., and Pratico D. MRI and CSF studies in the early diagnosis of Alzheimer's disease J. Intern. Med. 256 3 2004 205 223 10.1111/j.1365-2796.2004.01381.x 15324364
17. Duara R., Loewenstein D.A., Potter E., and Appel J. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease Neurology 71 24 2008 1986 1992 10.1212/01.wnl.0000336925.79704.9f 19064880
18. Elder G.A., Gama Sosa M.A., and De Gasperi R. Transgenic mouse models of Alzheimer's disease Mt Sinai J. Med. 77 1 2010 69 81 10.1002/msj.20159 20101721
19. Fayed N., Modrego P.J., Salinas G.R., and Gazulla J. Magnetic resonance imaging based clinical research in Alzheimer's disease J. Alzheimers Dis. 31 Suppl. 3 2012 S5 S18 10.3233/JAD-2011-111292 22233763
20. Frisoni G.B., Fox N.C., Jack C.R. Jr., Scheltens P., and Thompson P.M. The clinical use of structural MRI in Alzheimer disease Nat. Rev. Neurol. 6 2 2010 67 77 10.1038/nrneurol.2009.215 20139996
21. Hampel H., and Blennow K. CSF tau and beta-amyloid as biomarkers for mild cognitive impairment Dialogues Clin. Neurosci. 6 4 2004 379 390 22034251
22. Hampel H., Bürger K., Pruessner J.C., Zinkowski R., and DeBernardis J. Correlation of cerebrospinal fluid levels of Tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease Arch. Neurol. 62 5 2005 770 773 10.1001/archneur.62.5.770 15883264
23. Hansson O., Zetterberg H., Buchhave P., Londos E., and Blennow K. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol. 5 3 2006 228 234 10.1016/S1474-4422(06)70355-6 16488378
24. Haris M., Singh A., Cai K., McArdle E., and Fenty M. T(1ρ) MRI in Alzheimer's disease: detection of pathological changes in medial temporal lobe J. Neuroimaging 21 2 2011 e86 ee90 10.1111/j.1552-6569.2010.00467.x 20331502
25. Harwood D.G., Sultzer D.L., and Wheatley M.V. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances Neuropsychiatry Neuropsychol. Behav. Neurol. 13 2 2000 83 88 10780626
26. Herukka S.K., Pennanen C., Soininen H., and Pirttilä T. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy J. Alzheimers Dis. 14 1 2008 51 57 18525127
27. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., and Riemenschneider M. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 8 1999 1555 1562 10.1212/WNL.52.8.1555 10331678
28. Jack C.R. Jr., Petersen R.C., Xu Y.C., Waring S.C., and O'Brien P.C. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease Neurol. 49 3 1997 786 794 10.1212/WNL.49.3.786 9305341
29. Kadir A., Almkvist O., Forsberg A., Wall A., and Engler H. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease Neurobiol. Aging 33 1 2012 10.1016/j.neurobiolaging.2010.06.015 20688420
30. Koppel J., Goldberg T.E., Gordon M.L., Huey E., and Davies P. Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis Am. J. Geriatr. Psychiatry 20 11 2012 994 1000 10.1097/JGP.0b013e3182358921 22048323
31. Li L.Z., Xu H.N., and Reddy R. Characterizing breast cancer mouse xenografts with T(1)rho -MRI: a preliminary study Adv. Exp. Med. Biol. 701 2011 137 142
32. Mattsson N., Zetterberg H., Hansson O., Andreasen N., and Parnetti L. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 4 2009 385 393 10.1001/jama.2009.1064 19622817
33. McKhann G., Drachman D., Folstein M., Katzman R., and Price D. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurol. 34 7 1984 939 944 10.1212/WNL.34.7.939 6610841
34. Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., and Schröter A. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurology 54 5 2000 1099 1102 10.1212/WNL.54.5.1099 10720281
35. Parnetti L., Lanari A., Amici S., Gallai V., and Vanmechelen E. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group Neurol. Sci. 22 1 2001 77 78 10.1007/s100720170055 11487210
36. Pearson S.D., Ollendorf D.A., and Colby J.A. Amyloid-beta positron emission tomography in the diagnostic evaluation of Alzheimer disease: summary of primary findings and conclusions JAMA Intern. Med. 2013
37. Petersen R.C., Doody R., Kurz A., Mohs R.C., and Morris J.C. Current concepts in mild cognitive impairment Arch. Neurol. 58 12 2001 1985 1992 10.1001/archneur.58.12.1985 11735772
38. Regatte R.R., Akella S.V., Wheaton A.J., Lech G., and Borthakur A. 3D-T1rho-relaxation mapping of articular cartilage: in vivo assessment of early degenerative changes in symptomatic osteoarthritic subjects Acad. Radiol. 11 7 2004 741 749 10.1016/j.acra.2004.03.051 15217591
39. Reijn T.S., Rikkert M.O., van Geel W.J., de Jong D., and Verbeek M.M. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins Clin. Chem. 53 5 2007 859 865 10.1373/clinchem.2006.081679 17395712
40. Richard E., Schmand B.A., Eikelenboom P., Van Gool W.A. Alzheimer's Disease Neuroimaging Initiative MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study BMJ Open 3 6 2013 10.1136/bmjopen-2012-002541 23794572
41. Schuff N., Woerner N., Boreta L., Kornfield T., and Shaw L.M. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers Brain 132 4 2009 1067 1077 10.1093/brain/awp007 19251758
42. Singh A., Haris M., Cai K., Kogan F., and Hariharan H. High resolution T1rho mapping of in vivo human knee cartilage at 7T PLOS One 9 5 2014 e97486 10.1371/journal.pone.0097486 24830386
43. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., and Barkhof F. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study Neurobiol. Aging 31 5 2010 758 764 10.1016/j.neurobiolaging.2008.06.016 18692273
44. Tam C.W., Burton E.J., McKeith I.G., Burn D.J., and O'Brien J.T. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies Neurology 64 5 2005 861 865 10.1212/01.WNL.0000153070.82309.D4 15753423
45. Urakami K., Wada K., Arai H., Sasaki H., and Kanai M. Diagnostic significance of Tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy J. Neurol. Sci. 183 1 2001 95 98 10.1016/S0022-510X(00)00480-9 11166802
46. Vanderstichele H., Bibl M., Engelborghs S., Le Bastard N., and Lewczuk P. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers Standardization Initiative Alzheimers Dement. 8 1 2012 65 73 10.1016/j.jalz.2011.07.004 22047631
47. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., and Trojanowski J.Q. Serial MRI and CSF biomarkers in normal aging, MCI, and AD Neurology 75 2 2010 143 151 10.1212/WNL.0b013e3181e7ca82 20625167
48. Watts R., Andrews T., Hipko S., Gonyea J.V., and Filippi C.G. In vivo whole-brain T1-rho mapping across adulthood: normative values and age dependence J. Magn. Reson. Imaging 40 2014 376 382 10.1002/jmri.24358 24227659
49. Wheaton A.J., Dodge G.R., Elliott D.M., Nicoll S.B., and Reddy R. Quantification of cartilage biomechanical and biochemical properties via T1rho magnetic resonance imaging Magn. Reson. Med. 54 5 2005 1087 1093 10.1002/mrm.20678 16200568
50. Wiltfang J., Esselmann H., Smirnov A., Bibl M., and Cepek L. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Ann. Neurol. 54 2 2003 263 267 10.1002/ana.10661 12891683
51. Witschey W.R., Borthakur A., Fenty M., Kneeland B.J., and Lonner J.H. T1rho MRI quantification of arthroscopically confirmed cartilage degeneration Magn. Reson. Med. 63 5 2010 1376 1382 10.1002/mrm.22272 20432308
52. Zhang S., Han D., Tan X., Feng J., and Guo Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment Int. J. Clin. Pract. 66 2 2012 185 198 10.1111/j.1742-1241.2011.02845.x 22257044